JP5890553B2 - 固体組成物 - Google Patents
固体組成物 Download PDFInfo
- Publication number
- JP5890553B2 JP5890553B2 JP2015051690A JP2015051690A JP5890553B2 JP 5890553 B2 JP5890553 B2 JP 5890553B2 JP 2015051690 A JP2015051690 A JP 2015051690A JP 2015051690 A JP2015051690 A JP 2015051690A JP 5890553 B2 JP5890553 B2 JP 5890553B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solid
- compound
- surfactant
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Peptides Or Proteins (AREA)
Description
WinNonlin 5.2(Pharsight、Mountain View、CA)を用い、非コンパートメント解析を用いて、化合物Iおよびリトナビルの薬物動態学的(PK)パラメーターを見積もった。定量化の限界を下回る値はゼロで置き換えた。欠測値は、それらが決して抜き出されないかのごとくに扱われた。手順に明記される公称の採血時間および用量を、PK解析のために使用した。
投与量標準化AUC∞ 時間0から無限大までの投与量標準化濃度対時間曲線下面積(AUC∞またはAUC(0−Inf):)
投与量標準化Cmax 観測される最大血漿中濃度の投与量標準化したもの:
結晶性一水和物および二水和物の形態の化合物Iを、親水性ポリマーおよび医薬として許容される界面活性剤と様々な比で混合し、有機溶媒(アセトンまたはエタノール/水混合物)中に溶解させた。次いで加熱下(75℃)および真空下でGenevacロータリーエバポレーターまたはBuchi Rotavapを用いて溶媒を系から除去した。異なる界面活性剤またはポリマーを用いた様々な薬剤添加レベルの化合物Iの固体分散物を30メッシュスクリーンによってふるい分けして粒径を小さくした。得られる固体分散物試料を、粉末X線回折(PXRD)による非結晶の特性決定、化学的安定性、インビトロ溶解性試験およびイヌのバイオアベイラビリティーの調査に使用した。
噴霧乾燥を用いて2つの錠剤処方物を調製して、ポリマーマトリックス中の非晶質化合物Iの固体分散物粉末を得た。第1の錠剤処方物において、噴霧乾燥粉末は17.5重量%の化合物I、72.5重量%のコポビドン、および10重量%のポリソルバート80を含有した。第2の錠剤処方物において、噴霧乾燥粉末は17.5重量%の化合物I、72.5重量%のコポビドン、7重量%のプロピレングリコールモノラウラート、および3重量%のビタミンE TPGSを含有した。両方の処方物において、アセトンを噴霧乾燥における溶媒として使用した。
化合物Iおよびリトナビルを、溶融押出を用いて共押出した。4つの押出物を調製し、次いで粉砕しカプセル中に充填した。第1の押出物は、化合物I、リトナビル、コポビドン、ラウログリコールFCC、およびビタミンE TPGSを10:5:77:5:3の重量比で含有した(以下処方物1)。第2の押出物は、化合物I、リトナビル、コポビドン、およびポリソルバート80を15:7.5:67.5:10の重量比で含有した(以下処方物2)。第3の押出物は、化合物I、リトナビル、コポビドン、ラウログリコールFCC、およびビタミンE TPGSを10:5:79:4:2の重量比で含有した(以下処方物3)。第4の押出物は、化合物I、リトナビル、コポビドン、ラウログリコールFCC、およびビタミンE TPGSを15:7.5:69.5:5:3の重量比で含有した(以下処方物4)。これらの押出物カプセルの各々は、50mgの化合物Iおよび25mgのリトナビルを含有した。
Claims (18)
- (1)非晶質の形態の(2R,6S,13aS,14aR,16aS,Z)−N−(シクロプロピルスルホニル)−6−(5−メチルピラジン−2−カルボキサミド)−5,16−ジオキソ−2−(フェナントリジン−6−イルオキシ)−1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a−ヘキサデカヒドロシクロプロパ[e]ピロロ[1,2−a][1,4]ジアザシクロペンタデシン−14a−カルボキサミド、またはその医薬として許容される塩;
(2)医薬として許容される親水性ポリマー;および
(3)医薬として許容される界面活性剤
含む固体組成物の、HCV感染の治療のための医薬の製造のための使用。 - 前記固体組成物が、
(1)前記(2R,6S,13aS,14aR,16aS,Z)−N−(シクロプロピルスルホニル)−6−(5−メチルピラジン−2−カルボキサミド)−5,16−ジオキソ−2−(フェナントリジン−6−イルオキシ)−1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a−ヘキサデカヒドロシクロプロパ[e]ピロロ[1,2−a][1,4]ジアザシクロペンタデシン−14a−カルボキサミド、またはその医薬として許容される塩、および
(2)前記ポリマー
を含む固体分散物を含む、請求項1に記載の使用。 - 前記ポリマーが少なくとも50℃のTgを有する、請求項2に記載の使用。
- 前記界面活性剤が少なくとも10のHLB値を有する、請求項3に記載の使用。
- 10未満のHLB値を有する別の界面活性剤をさらに含む、請求項4に記載の使用。
- 前記固体分散物が前記界面活性剤をさらに含む非晶質固体分散物である、請求項3に記載の使用。
- 前記ポリマーがN−ビニルピロリドンのホモポリマーまたはコポリマーである、請求項3に記載の使用。
- 前記ポリマーがコポビドンである、請求項2に記載の使用。
- 前記界面活性剤がプロピレングリコールラウラートである、請求項8に記載の使用。
- 前記固体組成物がD−α−トコフェリルポリエチレングリコール1000スクシナートをさらに含む、請求項9に記載の使用。
- 前記界面活性剤がポリソルバートである、請求項8に記載の使用。
- 前記界面活性剤がポリソルバート80である、請求項8に記載の使用。
- 前記固体分散物が非晶質固体分散物である、請求項8に記載の使用。
- 前記固体分散物が前記界面活性剤を含む固溶体である、請求項8に記載の使用。
- 前記固体組成物がリトナビルをさらに含む、請求項1に記載の使用。
- 前記固体分散物がリトナビルをさらに含む、請求項2に記載の使用。
- 前記固体分散物がリトナビルをさらに含む、請求項6に記載の使用。
- 前記固溶体がリトナビルをさらに含む、請求項14に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33996410P | 2010-03-10 | 2010-03-10 | |
US61/339,964 | 2010-03-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012557164A Division JP5717768B2 (ja) | 2010-03-10 | 2011-03-08 | 固体組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015145387A JP2015145387A (ja) | 2015-08-13 |
JP5890553B2 true JP5890553B2 (ja) | 2016-03-22 |
Family
ID=44564075
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012557164A Active JP5717768B2 (ja) | 2010-03-10 | 2011-03-08 | 固体組成物 |
JP2015051690A Expired - Fee Related JP5890553B2 (ja) | 2010-03-10 | 2015-03-16 | 固体組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012557164A Active JP5717768B2 (ja) | 2010-03-10 | 2011-03-08 | 固体組成物 |
Country Status (27)
Country | Link |
---|---|
US (1) | US20110312973A1 (ja) |
EP (1) | EP2544689B1 (ja) |
JP (2) | JP5717768B2 (ja) |
KR (1) | KR101579079B1 (ja) |
CN (2) | CN104771364B (ja) |
AR (1) | AR081736A1 (ja) |
AU (1) | AU2011224558B2 (ja) |
BR (1) | BR112012022774A2 (ja) |
CA (1) | CA2792601C (ja) |
CL (1) | CL2012002500A1 (ja) |
CO (1) | CO6640208A2 (ja) |
DO (1) | DOP2012000245A (ja) |
EA (1) | EA021570B1 (ja) |
EC (1) | ECSP12012148A (ja) |
ES (1) | ES2613608T3 (ja) |
GT (1) | GT201200257A (ja) |
IL (1) | IL221833A (ja) |
MX (1) | MX2012010478A (ja) |
MY (1) | MY156888A (ja) |
NZ (1) | NZ602288A (ja) |
PE (1) | PE20130198A1 (ja) |
SG (1) | SG183985A1 (ja) |
TW (1) | TWI490218B (ja) |
UA (1) | UA104517C2 (ja) |
UY (1) | UY33265A (ja) |
WO (1) | WO2011112558A2 (ja) |
ZA (1) | ZA201207093B (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2593463T1 (sl) * | 2010-07-12 | 2020-10-30 | Salix Pharmaceuticals, Inc. | Formulacije rifaksimina in njihove uporabe |
KR20140003521A (ko) * | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제 |
US9044480B1 (en) | 2011-03-03 | 2015-06-02 | Abbvie Inc. | Compositions and methods for treating HCV |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
WO2013040568A1 (en) * | 2011-09-16 | 2013-03-21 | Abbvie Inc. | Methods for treating hcv |
AU2013201758B2 (en) * | 2011-10-21 | 2014-11-27 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
AU2015100283B4 (en) * | 2011-10-21 | 2015-06-18 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
ES2572355B1 (es) * | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de aad para uso en el tratamiento del vhc |
WO2013059638A1 (en) * | 2011-10-21 | 2013-04-25 | Abbvie Inc. | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
CN103826627B (zh) * | 2011-10-21 | 2016-02-24 | 艾伯维公司 | 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途 |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
JP2015522022A (ja) | 2012-06-27 | 2015-08-03 | アッヴィ・インコーポレイテッド | Hcvの処置に使用するためのabt−450およびリトナビルおよび例えばabt−072および/またはabt−333の併用処置 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
NZ630435A (en) * | 2012-07-12 | 2016-11-25 | Abbvie Inc | Crystalline forms of an hcv inhibitor |
WO2014043208A1 (en) * | 2012-09-11 | 2014-03-20 | Medivation Prostate Therapeutics, Inc. | Formulations of enzalutamide |
AU2012392557B2 (en) | 2012-10-19 | 2017-06-01 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
US20150011481A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for Treating HCV |
EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
US20150141351A1 (en) * | 2013-11-18 | 2015-05-21 | AbbVie Deutschland GmbH & Co. KG | Solid Pharmaceutical Compositions |
WO2015084953A1 (en) | 2013-12-04 | 2015-06-11 | Abbvie Inc. | Crystal forms |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
US20150209403A1 (en) | 2014-01-28 | 2015-07-30 | Abbvie Inc. | Dose Adjustment |
EP3157569B1 (en) * | 2014-06-18 | 2019-07-24 | F.Hoffmann-La Roche Ag | New pharmaceutical composition comprising non-ionic surfactants |
US20160074462A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Method of Treating HCV |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
MX2018002461A (es) * | 2015-08-28 | 2018-06-07 | Caliway Biopharmaceuticals Co Ltd | Una composicion farmaceutica para reducir la grasa localizada y sus usos. |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
EP4137132A1 (en) | 2016-09-30 | 2023-02-22 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
CA3056614C (en) | 2017-03-15 | 2023-09-26 | Cerecin Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
US10004719B1 (en) | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
IL283450B2 (en) * | 2018-11-30 | 2024-06-01 | Chemocentryx Inc | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses |
WO2023154171A1 (en) * | 2022-02-14 | 2023-08-17 | Purdue Research Foundation | Polymer salts for improved drug delivery from amorphous solid dispersions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
WO2004093915A1 (en) * | 2003-04-02 | 2004-11-04 | Boehringer Ingelheim International, Gmbh | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
CN1274300C (zh) * | 2003-12-11 | 2006-09-13 | 中国科学院生物物理研究所 | 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法 |
US20060068007A1 (en) * | 2004-09-24 | 2006-03-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Class of surfactant-like materials |
TW200716631A (en) * | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
TWI383980B (zh) * | 2005-07-29 | 2013-02-01 | Tibotec Pharm Ltd | C型肝炎病毒之大環抑制劑 |
UY30437A1 (es) * | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
AU2008340430B2 (en) * | 2007-12-21 | 2013-01-24 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
JP2011519364A (ja) * | 2008-04-15 | 2011-07-07 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
JP2011530532A (ja) * | 2008-08-07 | 2011-12-22 | シェーリング コーポレイション | 固体分子分散物中のhcvプロテアーゼインヒビターの薬学的処方物 |
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
EP2346329B1 (en) * | 2008-10-09 | 2013-08-21 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US8476225B2 (en) * | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
-
2011
- 2011-03-08 KR KR1020127026358A patent/KR101579079B1/ko active Protection Beyond IP Right Term
- 2011-03-08 CN CN201510101125.8A patent/CN104771364B/zh not_active Expired - Fee Related
- 2011-03-08 SG SG2012066924A patent/SG183985A1/en unknown
- 2011-03-08 NZ NZ602288A patent/NZ602288A/en not_active IP Right Cessation
- 2011-03-08 AU AU2011224558A patent/AU2011224558B2/en not_active Ceased
- 2011-03-08 CA CA2792601A patent/CA2792601C/en not_active Expired - Fee Related
- 2011-03-08 JP JP2012557164A patent/JP5717768B2/ja active Active
- 2011-03-08 CN CN201180023346.8A patent/CN103118681B/zh not_active Expired - Fee Related
- 2011-03-08 ES ES11753907.2T patent/ES2613608T3/es active Active
- 2011-03-08 EA EA201290892A patent/EA021570B1/ru not_active IP Right Cessation
- 2011-03-08 US US13/042,805 patent/US20110312973A1/en not_active Abandoned
- 2011-03-08 UA UAA201211694A patent/UA104517C2/uk unknown
- 2011-03-08 WO PCT/US2011/027511 patent/WO2011112558A2/en active Application Filing
- 2011-03-08 MY MYPI2012700621A patent/MY156888A/en unknown
- 2011-03-08 MX MX2012010478A patent/MX2012010478A/es active IP Right Grant
- 2011-03-08 EP EP11753907.2A patent/EP2544689B1/en active Active
- 2011-03-08 PE PE2012001536A patent/PE20130198A1/es active IP Right Grant
- 2011-03-08 BR BR112012022774A patent/BR112012022774A2/pt active Search and Examination
- 2011-03-09 UY UY0001033265A patent/UY33265A/es not_active Application Discontinuation
- 2011-03-10 AR ARP110100756A patent/AR081736A1/es unknown
- 2011-03-10 TW TW100108152A patent/TWI490218B/zh not_active IP Right Cessation
-
2012
- 2012-09-07 DO DO2012000245A patent/DOP2012000245A/es unknown
- 2012-09-09 IL IL221833A patent/IL221833A/en not_active IP Right Cessation
- 2012-09-10 CL CL2012002500A patent/CL2012002500A1/es unknown
- 2012-09-10 CO CO12154969A patent/CO6640208A2/es not_active Application Discontinuation
- 2012-09-10 GT GT201200257A patent/GT201200257A/es unknown
- 2012-09-10 EC ECSP12012148 patent/ECSP12012148A/es unknown
- 2012-09-20 ZA ZA2012/07093A patent/ZA201207093B/en unknown
-
2015
- 2015-03-16 JP JP2015051690A patent/JP5890553B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5890553B2 (ja) | 固体組成物 | |
US8686026B2 (en) | Solid compositions | |
TW201311245A (zh) | 醫藥組成物 | |
AU2014200725A1 (en) | Solid compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5890553 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |